The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.
Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.
The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.
The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.
The percentage of patients with stage I disease increased from 23.5% in 2010 to 29.1% in 2017.
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
The lack of guideline-concordant care for early-stage non-small cell lung cancer may affect the interpretation of adjuvant trial results, according to researchers.
Researchers sought to determine whether use of tumor match and adaptive RT improved incidence of adverse events and survival outcomes in patients with NSCLC.
Factors associated with greater odds of nonconcordant radiotherapy included receipt of major procedures or chemotherapy and survival more than 30 days after the treatment planning appointment.
